References
- Murdoch D, Sager J. Will targeted therapy hold its promise? An evidence-based review. Curr Opin Oncol 2008;20:104–11.
- Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, . Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531–41.
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, . Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567–78.
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
- Mariotto AB, Rowland JH, Ries LA, Scoppa S, Feuer EJ. Multiple cancer prevalence: A growing challenge in long-term survivorship. Cancer Epidemiol Biomarkers Prev 2007;16:566–71.